Wide Ranks

MRVI

Maravai LifeSciences Holdings,

5.92

Top Statistics
Market Cap 1 B Forward PE -104.30 Revenue Growth -2.50 %
Current Ratio 10.74 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -81.13 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1103.17 Enterprise / Revenue 4.13 Price To Sales Trailing12 Months 5.40
Profitability
Profit Margins -81.13 % Operating Margins -23.09 %
Balance Sheet
Total Cash 578 M Total Cash Per Share 4.08 Total Debt 613 M
Total Debt To Equity 100.03 Current Ratio 10.74 Book Value Per Share 2.44
All Measures
Short Ratio 310.00 % Message Board Id finmb_573282023 Shares Short Prior Month 8 M
Return On Equity -0.4293 City San Diego Uuid 90f7b200-f7ec-34b8-a9f6-f1c65d6979bf
Previous Close 5.62 First Trade Date Epoch Utc 1 B Book Value 2.44
Beta 0.0240 Total Debt 613 M Volume 2 M
Price To Book 2.43 Fifty Two Week Low 4.28 Total Cash Per Share 4.08
Total Revenue 276 M Shares Short Previous Month Date 1 B Target Median Price 9.50
Audit Risk 2 Max Age 86400 Recommendation Mean 1.87
Sand P52 Week Change 0.3133 Operating Margins -23.09 % Target Mean Price 9.72
Net Income To Common -224660000 Short Percent Of Float 0.0585 Implied Shares Outstanding 123 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 578 M Next Fiscal Year End 1 B
Revenue Per Share 2.04 Held Percent Insiders 0.0137 Ebitda Margins 0.37 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 7 Regular Market Previous Close 5.62 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.16 Open 5.62
Free Cashflow 8 M State CA Dividend Yield 0.00 %
Return On Assets -0.0161 Time Zone Short Name EST Board Risk 10
Trailing Eps -1.67 Day Low 5.61 Address1 10770 Wateridge Circle
Shares Outstanding 141 M Compensation Risk 5 Price Hint 2
Target High Price 13.20 Website https://www.maravai.com 52 Week Change 0.1608
Average Volume 1 M Recommendation Key buy Forward Eps 0.0000
Compensation As Of Epoch Date 1 B Quick Ratio 959.90 % Is_sp_500 False
Regular Market Day High 6.00 Profit Margins -81.13 % Debt To Equity 100.03
Fifty Two Week High 11.55 Day High 6.00 Shares Short 6 M
Regular Market Open 5.62 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 4.13 Revenue Growth -2.50 % Shares Percent Shares Out 0.0491
Operating Cashflow 29 M Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 92121
Quote Type EQUITY Industry Biotechnology Long Name Maravai LifeSciences Holdings, Inc.
Overall Risk 7 Regular Market Day Low 5.61 Held Percent Institutions 1.03
Current Price 5.92 Address2 Suite 200 Enterprise To Ebitda 1103.17
Financial Currency USD Current Ratio 10.74 Gross Margins 46.36 %
Industry Disp Biotechnology Number Of Analyst Opinions 12 Country United States
Float Shares 98 M Two Hundred Day Average 8.09 Governance Epoch Date 1 B
Enterprise Value 1 B Price To Sales Trailing12 Months 5.40 Forward PE -104.30
Regular Market Volume 2 M Ebitda 1 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.

The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology.

The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.

This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.

The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.

The company was incorporated in 2020 and is headquartered in San Diego, California.